Company intelligence / Profile preview

Olathe

Ownership: Private
Development stage: Other

Overview

Phoreus Biotech has not publicly disclosed clinical trial results. Its main achievements are proof-of-concept data supporting improved stability, targeted delivery, and elimination of cold-chain requirements for nucleic acid therapeutics such as mRNA vaccines. The BAPtofect® reagent kit is available for cell transfection research use.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Peptide nanoparticle delivery systemsSmall molecule (as cargo)Protein (as cargo)Nucleic acid (as cargo; e.g., mRNA)Peptide (as cargo)
Industry: Non-Drug Biotech

Partnerships

Academic institutions including Kansas State UniversityIndustry partnerships ongoing

Beyond the preview

Go deeper on Olathe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olathe.

Explore the full profile